Page last updated: 2024-11-05

u 0521

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

U 0521: catechol methyltransferase antagonist; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21632
CHEMBL ID353187
CHEBI ID79967
SCHEMBL ID8471397
MeSH IDM0048217

Synonyms (38)

Synonym
3',4'-dihydroxy-2-methylpropiophenone
1-propanone,4-dihydroxyphenyl)-2-methyl-
propiophenone,4'-dihydroxy-.alpha.-methyl-
nsc-27389
mls000738074 ,
propiophenone,4'-dihydroxy-2-methyl-
3',4'-dihydroxy-.alpha.-methylpropiophenone
nsc27389
isobutyrophenone,4'-dihydroxy-
5466-89-7
u 0521
brn 2093432
propiophenone, 3',4'-dihydroxy-2-methyl-
3',4'-dihydroxy-alpha-methylpropiophenone
nsc 27389
propiophenone, 3',4'-dihydroxy-alpha-methyl-
3',4'-dihydroxyisobutyrophenone
1-propanone, 1-(3,4-dihydroxyphenyl)-2-methyl-
isobutyrophenone, 3',4'-dihydroxy-
1-(3,4-dihydroxyphenyl)-2-methyl-1-propanone
u-0521
3', 4'-dihydroxy-2-methylpropiophenone
smr000393746
1-(3,4-dihydroxyphenyl)-2-methylpropan-1-one
CHEMBL353187 ,
chebi:79967 ,
1-(3,4-dihydroxy-phenyl)-2-methyl-propan-1-one
bdbm50017850
NCGC00246924-01
u0521
AKOS006241808
HMS2765J17
SCHEMBL8471397
DTXSID40203119
Q27149134
MS-22956
HY-121949
CS-0083733

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" After the strips had been contracted by 3x10-6M phenylephrine, a concentration which was able to produce an about 90% maximal contraction, dose-response curves to the relaxant effect of isoprenaline were determined in the absence and in the presence of U-0521 (10-4M)."( Relation between the amount of smooth muscle of venous tissue and the degree of supersensitivity to isoprenaline caused by inhibition of catechol-O-methyl transferase.
Azevedo, I; Cardoso, W; GuimarĂ£es, S; Oliveira, MC, 1975
)
0.25
" In addition, the effect on the norepinephrine dose-response curve of the combination of a methyixanthine and U-0521,the latter a potent inhibitor of catechol O-methyltransferase, the major enzyme of catecholamine inactivation in vascular tissue, did not differ from that of U-0521 alone."( Mechanism of methylxanthine sensitization of norepinephrine responses in a coronaryartery.
Frew, RD; Kalsner, S; Smith, GM, 1975
)
0.25
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acetophenonesA class or aromatic ketone consisting of acetophenone, PhC(=O)CH3, and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency25.11890.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency7.07950.125919.1169125.8920AID2549
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
phosphopantetheinyl transferaseBacillus subtilisPotency100.00000.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency31.62280.707912.194339.8107AID720542
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency7.07950.036619.637650.1187AID2100
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency5.62340.15855.287912.5893AID540303
Guanine nucleotide-binding protein GHomo sapiens (human)Potency1.77831.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dopamine beta-hydroxylaseHomo sapiens (human)IC50 (µMol)50.00001.20232.07793.0000AID62156
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)50.00000.00040.764912.5000AID127196
Catechol O-methyltransferaseRattus norvegicus (Norway rat)IC50 (µMol)6.00000.00222.81277.0795AID49921
Amine oxidase [flavin-containing] AMus musculus (house mouse)IC50 (µMol)50.00000.00004.85008.0000AID126362
large T antigenBetapolyomavirus macacaeIC50 (µMol)30.90000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
blood vessel remodelingDopamine beta-hydroxylaseHomo sapiens (human)
response to amphetamineDopamine beta-hydroxylaseHomo sapiens (human)
leukocyte mediated immunityDopamine beta-hydroxylaseHomo sapiens (human)
chemical synaptic transmissionDopamine beta-hydroxylaseHomo sapiens (human)
memoryDopamine beta-hydroxylaseHomo sapiens (human)
locomotory behaviorDopamine beta-hydroxylaseHomo sapiens (human)
visual learningDopamine beta-hydroxylaseHomo sapiens (human)
homoiothermyDopamine beta-hydroxylaseHomo sapiens (human)
vasoconstrictionDopamine beta-hydroxylaseHomo sapiens (human)
dopamine catabolic processDopamine beta-hydroxylaseHomo sapiens (human)
norepinephrine biosynthetic processDopamine beta-hydroxylaseHomo sapiens (human)
glucose homeostasisDopamine beta-hydroxylaseHomo sapiens (human)
fear responseDopamine beta-hydroxylaseHomo sapiens (human)
maternal behaviorDopamine beta-hydroxylaseHomo sapiens (human)
positive regulation of vasoconstrictionDopamine beta-hydroxylaseHomo sapiens (human)
behavioral response to ethanolDopamine beta-hydroxylaseHomo sapiens (human)
response to painDopamine beta-hydroxylaseHomo sapiens (human)
leukocyte migrationDopamine beta-hydroxylaseHomo sapiens (human)
positive regulation of cold-induced thermogenesisDopamine beta-hydroxylaseHomo sapiens (human)
regulation of vascular associated smooth muscle cell proliferationDopamine beta-hydroxylaseHomo sapiens (human)
regulation of vascular endothelial cell proliferationDopamine beta-hydroxylaseHomo sapiens (human)
regulation of extrinsic apoptotic signaling pathwayDopamine beta-hydroxylaseHomo sapiens (human)
octopamine biosynthetic processDopamine beta-hydroxylaseHomo sapiens (human)
hyaloid vascular plexus regressionTyrosine 3-monooxygenaseBos taurus (cattle)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
catalytic activityDopamine beta-hydroxylaseHomo sapiens (human)
dopamine beta-monooxygenase activityDopamine beta-hydroxylaseHomo sapiens (human)
copper ion bindingDopamine beta-hydroxylaseHomo sapiens (human)
protein bindingDopamine beta-hydroxylaseHomo sapiens (human)
L-ascorbic acid bindingDopamine beta-hydroxylaseHomo sapiens (human)
iron ion bindingTyrosine 3-monooxygenaseBos taurus (cattle)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
extracellular regionDopamine beta-hydroxylaseHomo sapiens (human)
extracellular spaceDopamine beta-hydroxylaseHomo sapiens (human)
cytoplasmDopamine beta-hydroxylaseHomo sapiens (human)
endoplasmic reticulumDopamine beta-hydroxylaseHomo sapiens (human)
membraneDopamine beta-hydroxylaseHomo sapiens (human)
transport vesicle membraneDopamine beta-hydroxylaseHomo sapiens (human)
secretory granule membraneDopamine beta-hydroxylaseHomo sapiens (human)
centriolar satelliteDopamine beta-hydroxylaseHomo sapiens (human)
chromaffin granule lumenDopamine beta-hydroxylaseHomo sapiens (human)
secretory granule lumenDopamine beta-hydroxylaseHomo sapiens (human)
chromaffin granule membraneDopamine beta-hydroxylaseHomo sapiens (human)
intracellular membrane-bounded organelleDopamine beta-hydroxylaseHomo sapiens (human)
synapseDopamine beta-hydroxylaseHomo sapiens (human)
extracellular spaceDopamine beta-hydroxylaseHomo sapiens (human)
secretory granule membraneDopamine beta-hydroxylaseHomo sapiens (human)
nucleusTyrosine 3-monooxygenaseBos taurus (cattle)
cytoplasmTyrosine 3-monooxygenaseBos taurus (cattle)
synaptic vesicleTyrosine 3-monooxygenaseBos taurus (cattle)
perinuclear region of cytoplasmTyrosine 3-monooxygenaseBos taurus (cattle)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID126362Inhibitory activity against the Monoamine oxidase A1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
AID62156Inhibitory activity against the dopamine beta hydroxylase1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
AID127196Inhibitory activity against the Monoamine oxidase B1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
AID62289Inhibitory activity against the dopamine decarboxylase1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
AID49921In vitro inhibitory activity against catechol O-methyltransferase of rat brain using 3,4-dihydroxybenzoic acid as the substrate.1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
AID213411Inhibitory activity against the tyrosine hydroxylase1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (61)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (80.33)18.7374
1990's7 (11.48)18.2507
2000's1 (1.64)29.6817
2010's3 (4.92)24.3611
2020's1 (1.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (1.61%)4.05%
Observational0 (0.00%)0.25%
Other61 (98.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]